Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;45(12):1467-1476.
doi: 10.1080/02713683.2020.1781193. Epub 2020 Jul 7.

Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept

Huan Liu  1   2 , Yue Ma  1 , Hong-Chang Xu  1 , Li-Ying Huang  1 , Li-Ying Zhai  1   3 , Xiao-Rong Zhang  1   2
Affiliations
Review

Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept

Huan Liu et al. Curr Eye Res. 2020 Dec.

Abstract

Purpose: To provide a detailed review on the therapeutic efficacy of conbercept for the management of ocular vasculopathies. Methods: A comprehensive literature search of various electronic databases was performed. Results: Ocular vasculopathy is one of the major causes of visual impairment and blindness which includes a range of disorders. Vascular endothelial growth factor (VEGF) regulates angiogenesis, enhances vascular permeability, and drives the formation of neovascularization. Anti-VEGF therapy has been shown to prevent vision loss or potentially improve vision in patients with exudative or neovascular retinal disease. The most recent anti-VEGF drug in China is conbercept. In the USA and Europe, bevacizumab is the most recently approved anti-VEGF agent. Conclusions: Conbercept serves as another anti-VEGF option for patients with neovascular AMD and other retinal vascular disorders. There have not been many clinical trials that study conbercept as compared with other currently available anti-VEGF drugs. There is a need for large-scale, well-designed, randomized clinical trials to ensure its long-term safety and efficacy and to determine if it has any advantages over other anti-VEGF agents.

Keywords: Age-related macular degeneration; branch retinal vein occlusion; conbercept; corneal neovascularization; diabetic retinopathy; myopic choroidal neovascularization; neovascular glaucoma; polypoidal choroidal vasculopathy; vascular endothelial growth factor.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

Substances

LinkOut - more resources